FDA 캘린더
미국 상장 바이오텍의 임상 데이터 발표, 임상 개시 및 진행 일정을 공식 근거와 함께 확인합니다.
FREE BETA · 비로그인도 오늘을 포함한 30일간의 일정을 볼 수 있습니다 (2026/11/10까지, 미국 동부 기준). 로그인하면 전체 캘린더를 이용할 수 있습니다.
일정 35/1612건 · 회사 26/429개
근거: A 규제기관·SEC·임상시험 등록기관 · B 회사 공식 자료 · 주가는 일정 근거와 별개의 시장 참고값입니다.
예정 일정
표를 좌우로 움직여 모든 열을 확인하세요 →
RESOLVE · Poster Presentation
A공식 원문출처 모두 보기 (2)
LEGEND · Webinar on surfactant plus detalimogene preclinical data and cohort enrollment guidance
B공식 원문
leniolisib Phase 2 · Additional data will be presented
A공식 원문출처 모두 보기 (2)
RESOLVE · Oral Abstract Session
A공식 원문출처 모두 보기 (2)
시험 상세
ORCA-OL · new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented
시험 상세
SL-846 IND-enabling GLP toxicology study · Preclinical data for SL-846, including safety, pharmacokinetics, and receptor occupancy from the ongoing GLP toxicology study
NCT05636618 · Cohort level safety and efficacy results
B공식 원문
NCT06253130 · will present clinical data from its ongoing Phase 1/2 trial of EIK1003
B공식 원문NCT06907043 · will also present, for the first time, data from an ongoing Phase 1/2 trial
B공식 원문NCT07262619 · Preliminary safety, tolerability and pharmacokinetic data for EIK1005 will be presented
B공식 원문
Himalayas-1 · A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1)
B공식 원문
COMPANION-002 · will highlight the results of the randomized, controlled Phase 2/3 COMPANION-002 clinical trial
B공식 원문
givastomig Phase 1b · Poster presentation of Phase 1b combination dose expansion data
B공식 원문출처 모두 보기 (2)
시험 상세
HARMONi-GI1 · data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured
TeLuRide-005 · will present comprehensive updated data from TeLuRide-005
B공식 원문시험 상세
Enozertinib Phase 1b · Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations
GB-4362 Phase 1 · accepted for poster presentation
A공식 원문
SARATOGA · Results will be highlighted
A공식 원문
TACTIC · A trial-in-progress poster on the MP0317 Phase 2 study has been accepted for presentation
B공식 원문
BB-301 Phase 1b/2a · Interim clinical results for Cohort 1 and Cohort 2 will be presented
B공식 원문
TUPELO · Additional Phase 2 safety and efficacy data from the TUPELO clinical trial contextualized with real world data
B공식 원문
시험 상세
lanifibranor Phase 2b · Lanifibranor Improved Liver Sinusoidal Endothelial Cell Dysfunction and Vascular Alterations Across All Stages From MASH To Cirrhosis
출처 모두 보기 (2)
시험 상세
Velinotamig Phase 1 · Multi-dose regimen data from the ongoing Genrix Bio Phase 1 dose escalation study in SLE to be shared
시험 상세
COMPLETE Trial · FT839: An Off-the-Shelf, Dual CAR T-Cell Therapy for the Comprehensive Elimination of Multicellular Drivers of Rheumatoid Arthritis
Ntrust Phase 1/2 studies · Preliminary Safety, PK/PD, and Clinical Activity
B공식 원문출처 모두 보기 (2)
SOLSTICE · Patterns of HDV RNA responses through Week 96
B공식 원문시험 상세
SOLSTICE · Intrahepatic NK cell remodelling with elebsiran and tobevibart in chronic hepatitis D - A translational sub-study of the SOLSTICE trial
Efficacy Reveals Biomarker Candidates for Fatigue in SLE
B공식 원문Ntrust Phase 1/2 studies · Preliminary Safety, PK/PD, and Clinical Activity
B공식 원문